News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
416 Results
Type
Article (40)
Company Profile (1)
Press Release (375)
Section
Business (111)
Career Advice (2)
Deals (21)
Drug Development (110)
FDA (5)
Job Trends (13)
News (247)
Policy (27)
Tag
Alliances (22)
ALS (1)
Alzheimer's disease (1)
Approvals (6)
Artificial intelligence (1)
Bankruptcy (1)
Best Places to Work (6)
Biotechnology (1)
Cancer (4)
Career advice (2)
Cell therapy (1)
Clinical research (93)
Collaboration (1)
COVID-19 (1)
C-suite (1)
Data (3)
Diagnostics (6)
Drug pricing (2)
Earnings (29)
Events (39)
Executive appointments (3)
FDA (9)
Frontotemporal dementia (1)
Funding (10)
Gene therapy (1)
Government (2)
Healthcare (1)
Immunology and inflammation (1)
Infectious disease (1)
IPO (14)
Job creations (5)
Job search strategy (2)
JPM (3)
Layoffs (3)
Legal (1)
Lung cancer (1)
Manufacturing (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (14)
Metabolic disorders (2)
Neuroscience (3)
NextGen: Class of 2026 (9)
Now hiring (2)
Obesity (2)
Ovarian cancer (1)
Parkinson's disease (1)
People (43)
Phase 1 (8)
Phase 2 (51)
Phase 3 (37)
Pipeline (3)
Postmarket research (3)
Preclinical (13)
Rare diseases (1)
Real estate (3)
Regulatory (31)
Research institute (1)
RNA editing (1)
Schizophrenia (1)
Series B (1)
Startups (8)
The Weekly (2)
Vaccines (4)
Venture capital (3)
Weight loss (2)
Date
Last 7 days (3)
Last 30 days (11)
Last 365 days (34)
2026 (12)
2025 (25)
2024 (13)
2023 (22)
2022 (26)
2021 (19)
2020 (14)
2019 (8)
2018 (8)
2017 (23)
2016 (20)
2015 (31)
2014 (24)
2013 (38)
2012 (35)
2011 (31)
2010 (27)
Location
Asia (14)
Australia (4)
California (14)
China (2)
Europe (30)
Illinois (1)
Massachusetts (5)
Nevada (1)
New York (2)
Northern California (6)
Pennsylvania (1)
South America (1)
Southern California (3)
United States (23)
416 Results for "eikon therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market
Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange.
January 29, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
February 5, 2026
·
3 min read
IPO
Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow
Analysts are cautiously optimistic about an IPO rebound for biopharma.
BioSpace
is keeping track of companies that seek to trade on the public markets this year.
February 6, 2026
·
5 min read
·
Tristan Manalac
Press Releases
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
December 3, 2025
·
2 min read
Funding
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
February 26, 2025
·
1 min read
·
Tristan Manalac
IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced their IPOs this year. Meanwhile, Aktis Oncology began trading publicly earlier this month.
January 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025
October 16, 2025
·
4 min read
Press Releases
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting
May 29, 2025
·
5 min read
Biotech Bay
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
May 28, 2024
·
3 min read
Press Releases
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology
February 19, 2025
·
4 min read
1 of 42
Next
